Plasminogen activator inhibitor-1 (PAI-1), encoded by the SERPINE1 gene, plays a complex biological role that transcends the exclusive control of the coagulation cascade. This serpinase acts as the main negative regulator of fibrinolysis through the direct inhibition of tissue plasminogen activator (tPA) and urokinase plasminogen activator (uPA). Consequently, the fine-tuning of this protein is essential for vascular homeostasis, since its overexpression correlates with a high risk of thrombotic events, such as acute myocardial infarction and stroke, while its molecular deficiency predisposes the body to hemorrhagic conditions.
Pleiotropic effects and cellular senescence
Scientific evidence demonstrates the involvement of PAI-1 in systemic pathophysiological processes, including pulmonary fibrosis, exacerbated mast cell activation, insulin resistance, and cognitive decline in neurodegenerative pathologies. PAI-1 expression increases progressively with physiological age and under the influence of stress hormones, specifically cortisol.
This chronic increase acts as an inducer of cellular senescence in fibroblasts, endothelial cells, and muscle stem cells. The accumulation of these senescent cells, which cease dividing but secrete pro-inflammatory factors, overwhelms the immune system’s clearance capacity, culminating in a state of low-grade chronic inflammation known as inflammaging.
Genomic determinants and dietary modulation
Individual genomic profiles significantly influence basal concentrations of this protein. The SERPINE1 gene polymorphism, particularly the 4G variant, is associated with a higher transcription rate and chronically elevated plasma levels of PAI-1.
From a biochemical modulation perspective, natural compounds such as hesperidin exhibit regulatory properties on this pathway. However, interventions with olive leaf extract require caution due to metabolic interaction with the catechol-O-methyltransferase enzyme, and are not recommended in individuals with the slow COMT phenotype. Additionally, diets rich in omega-6 polyunsaturated fatty acids, derived from industrial vegetable oils, enhance the expression of PAI-1, establishing a causal link between contemporary dietary patterns and the exacerbation of chronic pathologies.
Therapeutic perspectives and clinical trials
Current pharmacological research focuses on the development of specific inhibitory molecules for PAI-1, with multiple candidates in Phase II clinical trials. The target of these innovative therapies includes the treatment of chronic lung diseases, Alzheimer’s disease, and adjuvant oncology protocols.
The clinical success of these interventions depends on the precise calibration of the inhibition level, in order to mitigate fibrotic processes and plaque deposition without compromising physiological coagulation mechanisms and without increasing the risk of systemic bleeding.
